Predictive value of lipoprotein(a) for left atrial thrombus or spontaneous echo contrast in non-valvular atrial fibrillation patients with low CHA
Atrial fibrillation
CHA2DS2-VASc score
Left atrial spontaneous echo contrast
Left atrial thrombus
Lipoprotein(a)
Journal
Lipids in health and disease
ISSN: 1476-511X
Titre abrégé: Lipids Health Dis
Pays: England
ID NLM: 101147696
Informations de publication
Date de publication:
22 Jan 2024
22 Jan 2024
Historique:
received:
26
10
2023
accepted:
24
12
2023
medline:
23
1
2024
pubmed:
23
1
2024
entrez:
23
1
2024
Statut:
epublish
Résumé
Current guidelines are debated when it comes to starting anticoagulant therapy in patients with non-valvular atrial fibrillation (NVAF) and low CHA NVAF patients with available transesophageal echocardiography (TEE) data were evaluated. Based on the TEE results, the subjects were classified into non-LAT/SEC and LAT/SEC groups. The risk factors for LAT/SEC were examined using binary logistic regression analyses and were validated by using 1:1 propensity score matching (PSM). Subsequently, novel predictive models for LAT/SEC were developed by integrating the CHA In total, 481 NVAF patients were enrolled. The LAT/SEC group displayed higher Lp(a) concentrations. It was found that enlarged left atrial diameter (LAD), high concentrations of Lp(a), and a history of coronary heart disease (CHD) were independent predictors of LAT/SEC. Lp(a) and LAD still had predictive values for LAT/SEC after adjusting for PSM. In both the highest quartile groups of Lp(a) (>266 mg/L) and LAD (>39.5 mm), the occurrence of LAT/SEC was higher than that in the corresponding lowest quartile. By incorporating Lp(a) and the LAD, the predictive value of the CHA Elevated Lp(a) and enlarged LAD were independent risk factors for LAT/SEC among NVAF patients with low CHA Retrospectively registered.
Identifiants
pubmed: 38254171
doi: 10.1186/s12944-023-01990-1
pii: 10.1186/s12944-023-01990-1
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
22Subventions
Organisme : The Nature Science Foundation of China
ID : Grant No. 81873513, 81600574, and 30871042
Informations de copyright
© 2024. The Author(s).
Références
Jame S, Barnes G. Stroke and thromboembolism prevention in atrial fibrillation. Heart. 2020;106:10–7.
doi: 10.1136/heartjnl-2019-314898
pubmed: 31533990
Kim YG, Choi J-I, Kim M-N, Cho D-H, Oh S-K, Kook H, Park H-S, Lee KN, Baek Y-S, Roh S-Y. Non-vitamin K antagonist oral anticoagulants versus warfarin for the prevention of spontaneous echo-contrast and thrombus in patients with atrial fibrillation or flutter undergoing cardioversion: a trans-esophageal echocardiography study. PLoS One. 2018;13:e0191648.
doi: 10.1371/journal.pone.0191648
pubmed: 29360845
pmcid: 5779688
Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, Boriani G, Castella M, Dan G-A, Dilaveris PE. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS) The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42:373–498.
doi: 10.1093/eurheartj/ehaa612
pubmed: 32860505
Liu X-B, Jia Z-X, Xia S-J, He L, Lu S-X, Guo X-Y, Li S-N, Liu N, Jiang C-X, Sang C-H. The thromboembolism risk of low-risk atrial fibrillation patients with different clinical characteristics. Zhonghua xin xue Guan Bing za zhi. 2020;48:735–9.
pubmed: 32957755
Chao T-F, Liu C-J, Wang K-L, Lin Y-J, Chang S-L, Lo L-W, Hu Y-F, Tuan T-C, Chen T-J, Lip GY. Should atrial fibrillation patients with 1 additional risk factor of the CHA2DS2-VASc score (beyond sex) receive oral anticoagulation? J Am Coll Cardiol. 2015;65:635–42.
doi: 10.1016/j.jacc.2014.11.046
pubmed: 25677422
Hayden DT, Hannon N, Callaly E, D NC, Horgan G, Kyne L, Duggan J, Dolan E, O'Rourke K, Williams D, et al: Rates and Determinants of 5-Year Outcomes After Atrial Fibrillation-Related Stroke: A Population Study. Stroke. 2015; 46:3488-3493.
Ruscica M, Sirtori CR, Corsini A, Watts GF, Sahebkar A. Lipoprotein (a): Knowns, unknowns and uncertainties. Pharmacol Res. 2021;173:105812.
doi: 10.1016/j.phrs.2021.105812
pubmed: 34450317
Song J, Zhang X, Wei M, Bo Y, Zhou X, Tang B. Association between lipoprotein (a) and thromboembolism in patients with non-valvular atrial fibrillation: a cross-sectional study. Lipids Health Dis. 2022;21:78.
doi: 10.1186/s12944-022-01682-2
pubmed: 36002888
pmcid: 9404645
Igarashi Y, Kasai H, Yamashita F, Sato T, Inuzuka H, Ojima K, Aizawa Y. Lipoprotein (a), left atrial appendage function and thromboembolic risk in patients with chronic nonvalvular atrial fibrillation. Japan Circ J. 2000;64:93–8.
doi: 10.1253/jcj.64.93
Koca V, Bozat T, Akkaya V, Sarikamis C, Turk T, Vural H, Ozdemir A. Left atrial thrombus detection with multiplane transesophageal echocardiography: an echocardiographic study with surgical verification. J Heart Valve Dis. 1999;8:63–6.
pubmed: 10096484
Black IW, Hopkins AP, Lee LC, Walsh WF. Left atrial spontaneous echo contrast: a clinical and echocardiographic analysis. J Am Coll Cardiol. 1991;18:398–404.
doi: 10.1016/0735-1097(91)90592-W
pubmed: 1856407
Di Minno MND, Ambrosino P, Russo AD, Casella M, Tremoli E, Tondo C. Prevalence of left atrial thrombus in patients with non-valvular atrial fibrillation. Thromb Haemost. 2016;115:663–77.
doi: 10.1160/th15-07-0532
pubmed: 26607276
Whiteside H, Nagabandi A, Brown K, Ayyala DN, Sharma G. Prevalence and clinical characteristics associated with left atrial thrombus detection: Apixaban. J Am Coll Cardiol. 2019;73:417–417.
doi: 10.1016/S0735-1097(19)31025-3
Chen J, Zhou M, Wang H, Zheng Z, Rong W, He B, Zhao L. Risk factors for left atrial thrombus or spontaneous echo contrast in non-valvular atrial fibrillation patients with low CHA2DS2-VASc score. J Thromb Thromb. 2022;53:523–31.
doi: 10.1007/s11239-021-02554-9
Almorad A, Ohanyan A, Bentea GP, Wielandts J-Y, El Haddad M, Lycke M, O’Neill L, Morissens M, De Keyzer E, Nguyen T. D-dimer blood concentrations to exclude left atrial thrombus in patients with atrial fibrillation. Heart. 2021;107:195–200.
doi: 10.1136/heartjnl-2020-317612
pubmed: 33087410
Benjamin EJ, Virani SS, Callaway CW, Chamberlain AM, Chang AR, Cheng S, Chiuve SE, Cushman M, Delling FN, Deo R, et al. Heart Disease and Stroke Statistics-2018 Update: A Report From the American Heart Association. Circulation. 2018;137:e67–492.
doi: 10.1161/CIR.0000000000000558
pubmed: 29386200
Zhan Y, Joza J, Al Rawahi M, Barbosa RS, Samuel M, Bernier M, Huynh T, Thanassoulis G, Essebag V. Assessment and management of the left atrial appendage thrombus in patients with nonvalvular atrial fibrillation. Can J Cardiol. 2018;34:252–61.
doi: 10.1016/j.cjca.2017.12.008
pubmed: 29395705
Lip GY, Skjøth F, Rasmussen LH, Larsen TB. Oral anticoagulation, aspirin, or no therapy in patients with nonvalvular AF with 0 or 1 stroke risk factor based on the CHA2DS2-VASc score. J Am Coll Cardiol. 2015;65:1385–94.
doi: 10.1016/j.jacc.2015.01.044
pubmed: 25770314
Di Fusco SA, Maggioni AP, Scicchitano P, Zuin M, D’Elia E, Colivicchi F. Lipoprotein (a), Inflammation, and Atherosclerosis. J Clin Med. 2023;12:2529.
doi: 10.3390/jcm12072529
pubmed: 37048611
pmcid: 10095203
Duarte Lau F, Giugliano RP. Lipoprotein(a) and its significance in cardiovascular disease: A review. JAMA Cardiology. 2022;7:760–9.
Di Fusco SA, Arca M, Scicchitano P, Alonzo A, Perone F, Gulizia MM, Gabrielli D, Oliva F, Imperoli G, Colivicchi F. Lipoprotein (a): a risk factor for atherosclerosis and an emerging therapeutic target. Heart. 2023;109:18–25.
doi: 10.1136/heartjnl-2021-320708
Jawi MM, Frohlich J, Chan SY. Lipoprotein(a) the insurgent: A new insight into the structure, function, metabolism, pathogenicity, and medications affecting lipoprotein(a) molecule. J Lipids. 2020;2020:3491764.
Barre D. The molecular nature and consequences of lipoprotein (a)’s association with platelets. Protein Peptide Lett. 2007;14:839–42.
doi: 10.2174/092986607782110202
Jang AY, Han SH, Sohn IS, Oh PC, Koh KK. Lipoprotein(a) and cardiovascular diseases - revisited. Circ J 2020;84:867–74.
Vučković B, Đerić M. Lipoprotein (a): a link between thrombogenesis and atherogenesis. Medicinski Pregled. 2007;60:37–41.
doi: 10.2298/MPNS0702037V
pubmed: 17853709
Caplice NM, Panetta C, Peterson TE, Kleppe LS, Mueske CS, Kostner GM, Broze GJ Jr, Simari RD. Lipoprotein (a) binds and inactivates tissue factor pathway inhibitor: a novel link between lipoproteins and thrombosis. Blood. 2001;98:2980–7.
doi: 10.1182/blood.V98.10.2980
pubmed: 11698280
Wilson DP, Jacobson TA, Jones PH, Koschinsky ML, McNeal CJ, Nordestgaard BG, Orringer CE. Use of lipoprotein (a) in clinical practice: a biomarker whose time has come. A scientific statement from the National Lipid Association. J Clin Lipidol. 2019;13:374–92.
doi: 10.1016/j.jacl.2019.04.010
pubmed: 31147269
Lu W, Cheng Y-C, Chen K, Wang H, Gerhard GS, Still CD, Chu X, Yang R, Parihar A, O’Connell JR. Evidence for several independent genetic variants affecting lipoprotein (a) cholesterol levels. Hum Mol Genet. 2015;24:2390–400.
doi: 10.1093/hmg/ddu731
pubmed: 25575512
pmcid: 4380064
Zhang E, Liu T, Li Z, Zhao J, Li G. High CHA2DS2− VASc score predicts left atrial thrombus or spontaneous echo contrast detected by transesophageal echocardiography. Int J Cardiol. 2015;184:540–2.
doi: 10.1016/j.ijcard.2015.02.109
pubmed: 25767011
Zoni-Berisso M, Lercari F, Carazza T, Domenicucci S. Epidemiology of atrial fibrillation: European perspective. Clinical epidemiology. 2014;6:213.
doi: 10.2147/CLEP.S47385
pubmed: 24966695
pmcid: 4064952
Al Missary AMA. Echocardiographic Predictors of Non Rheumatic Atrial Fibrillation. Diyala J Med. 2011;1:33–6.
Higashiyama A, Kokubo Y, Watanabe M, Nakao YM, Okamura T, Okayama A, Miyamoto Y. Echocardiographic parameters and the risk of incident atrial fibrillation: the Suita study. J Epidemiol. 2020;30:183–7.
doi: 10.2188/jea.JE20180251
pubmed: 30930375
pmcid: 7064552
Chen YC, Voskoboinik A, La Gerche A, Marwick TH, McMullen JR. Prevention of pathological atrial remodeling and atrial fibrillation: JACC state-of-the-art review. J Am Coll Cardiol. 2021;77:2846–64.
doi: 10.1016/j.jacc.2021.04.012
pubmed: 34082914
Lin W-D, Xue Y-M, Liu F-Z, Fang X-H, Zhan X-Z, Liao H-T, Tse G, Wu S-L. Left atrial enlargement and non-paroxysmal atrial fibrillation as risk factors for left atrial thrombus/spontaneous Echo contrast in patients with atrial fibrillation and low CHA2DS2-VASc score. J Geriatr Cardiol. 2020;17:155.
pubmed: 32280332
pmcid: 7118018
Zhou M, Chen J, Wang H, Xi S, Gan T, Zhao L: Independent risk factors of atrial thrombosis in patients with nonvalvular atrial fibrillation and low CHA 2 DS 2-VASc scores. Nan Fang yi ke da xue xue bao= Journal of Southern Medical University. 2021; 41:1243-1249.
Hamatani Y, Ogawa H, Takabayashi K, Yamashita Y, Takagi D, Esato M, Chun Y-H, Tsuji H, Wada H, Hasegawa K. Left atrial enlargement is an independent predictor of stroke and systemic embolism in patients with non-valvular atrial fibrillation. Sci Rep. 2016;6:1–8.
doi: 10.1038/srep31042